Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era-Reference-Cited by-同舟云学术

Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era

Published:2013-02-08 Issue:2 Volume:8 Page:e55717
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Iqbal Zafar,Aleem Aamer,Iqbal Mudassar,Naqvi Mubashar Iqbal,Gill Ammara,Taj Abid Sohail,Qayyum Abdul,ur-Rehman Najeeb,Khalid Ahmad Mukhtar,Shah Ijaz Hussain,Khalid Muhammad,Haq Riazul,Khan Mahwish,Baig Shahid Mahmood,Jamil Abid,Abbas Muhammad Naeem,Absar Muhammad,Mahmood Amer,Rasool Mahmood,Akhtar Tanveer

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference46 articles.

1. Mechanisms of Disease: Chronic myeloid leukemia-advances in biology and new approaches to treatment;JM Goldman;N Engl J Med,2003

2. How I treat chronic myeloid leukemia in the imatinib era;JM Goldman;Blood,2007

3. Kantarjian H, Cortes J (2008) BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. J Natl Compr Canc Netw Suppl 2: S37–S42; quiz S43–S44.

4. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification;ME Gorre;Science,2001

5. GIMEMA Working Party on Chronic Myeloid Leukemia. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia;S Soverini;Clin Cancer Res,2006

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches;Clinical Drug Investigation;2024-01-05

2. Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia;Cancer Cell International;2023-04-06

3. Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era;Frontiers in Pediatrics;2022-06-23

4. Evaluation of residue variability in a conformation‐specific context and during evolutionary sequence reconstruction narrows drug resistance selection in Abl1 tyrosine kinase;Protein Science;2022-06-16

5. Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients;Leukemia Research;2021-12